Prostate Cancer: Symptoms, Diagnosis & Treatment

Where is the prostate gland located?

The prostate is a walnut-sized gland found only in men. It sits below the bladder, in front of the rectum, and surrounds the top of the urethra — the tube that carries urine and semen out of the body.

Its main job is producing fluid that nourishes and transports sperm, making up part of semen. Because it wraps around the urethra, an enlarged or diseased prostate can interfere with urination. That anatomical fact explains most prostate symptoms men experience.

Worth knowing: an enlarged prostate is usually not cancer. Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement that affects most men as they age, and it causes far more urinary symptoms than cancer does.

What is prostate cancer?

Prostate cancer occurs when cells in the prostate begin growing and dividing abnormally, forming a tumor. More than 95% of cases are adenocarcinomas, which arise from the gland cells that produce prostate fluid. Rarer types include small cell carcinoma, neuroendocrine tumors, transitional cell carcinoma, and sarcomas — these behave differently and are treated differently.

What makes prostate cancer unusual among cancers is how enormously variable it is. Some prostate cancers grow so slowly that a man will live a full life and die of something else entirely, never troubled by the tumor. Others are aggressive from the start and spread within a few years. Two men can both hear "you have prostate cancer" and be facing completely different situations.

This is why modern prostate cancer care is built around risk stratification — determining, as precisely as possible, which kind of cancer a man actually has before deciding what to do about it. A low-risk cancer that would never have caused harm can be monitored safely. A high-risk cancer needs decisive treatment. Distinguishing between them is the central task after diagnosis.

Prostate cancer growth is driven by androgens, chiefly testosterone and its more potent form, dihydrotestosterone (DHT). This is why hormone-blocking therapy works against advanced disease. It is worth correcting a persistent myth here: naturally high testosterone levels have not been shown to cause prostate cancer. Large pooled analyses have found no consistent link between a man’s circulating testosterone and his risk of developing the disease. Androgens fuel prostate cancer that already exists; they are not established as its cause.

Risk factors

Some risk factors you cannot change. Others you can influence. Knowing which category you fall into determines when you should start screening.

Non-modifiable risk factors

Age. Risk climbs steeply after 50. Prostate cancer is rare before 40 — only about 1% of cases occur before age 50 — and roughly 60% of diagnoses are in men 65 or older.

Family history. A man with a father or brother who had prostate cancer has roughly double the average risk. Risk rises further with multiple affected relatives or relatives diagnosed young. A family history of breast, ovarian, pancreatic, or colorectal cancer also matters, because some of the same inherited genes are involved.

Black ancestry. Black men in the United States are diagnosed at substantially higher rates — an estimated 200.1 cases per 100,000 in 2026, compared with 122.2 per 100,000 for White men — and are about twice as likely to die from the disease. They also tend to be diagnosed younger and at more advanced stages. The reasons involve a mix of genetic, environmental, and access-to-care factors that researchers are still untangling. The practical implication is clear: earlier screening.

Inherited genetic mutations. Pathogenic variants in BRCA2 carry the strongest known inherited risk, with BRCA1, HOXB13, ATM, CHEK2, and the Lynch syndrome mismatch-repair genes (MLH1, MSH2, MSH6, PMS2) also implicated. BRCA2 carriers in particular tend to develop more aggressive disease at younger ages. These mutations are also directly actionable — they open the door to PARP inhibitor therapy and have implications for a man’s blood relatives.

Agent Orange exposure. Vietnam-era veterans exposed to Agent Orange have an elevated risk, and the VA recognizes prostate cancer as a presumptive service-connected condition for these veterans.

Modifiable and possible risk factors

Obesity. Obesity does not appear to raise the risk of developing prostate cancer overall, but it is consistently associated with a higher risk of aggressive, advanced, and fatal disease. Obesity also makes PSA interpretation less reliable and prostate surgery technically harder.

Smoking. Heavy smoking is linked to higher prostate cancer mortality and a greater risk of recurrence after treatment. Risk declines after quitting.

Diet. The evidence here is suggestive rather than conclusive. Diets high in red and processed meat, high-fat dairy, and calcium supplementation above roughly 1,500 mg/day have been associated with increased risk of advanced disease in some studies. Diets rich in vegetables, tomatoes and other lycopene sources, fish, and healthy fats are associated with better outcomes. Nothing you eat causes or cures prostate cancer, and claims to the contrary — including the idea that caffeine, spicy food, or baked goods cause prostate cancer — are not supported by evidence.

Physical inactivity. Regular exercise is associated with lower prostate cancer mortality and better outcomes after diagnosis, and it is one of the few lifestyle interventions with reasonably consistent evidence behind it.

What causes prostate cancer?

At the cellular level, prostate cancer begins when DNA damage accumulates in prostate cells and disables the mechanisms that normally control growth and cell death. Most of this damage is acquired over a lifetime rather than inherited. About 5% to 10% of cases involve an inherited mutation passed down through families.

Researchers have identified more than 250 genetic variants that each nudge risk slightly, and combinations of these are being used to build polygenic risk scores — a research tool that may eventually help personalize screening.

But no single cause has been identified, and no test can predict with certainty who will develop prostate cancer. What we can do is identify who is at elevated risk, screen those men appropriately, and reduce the modifiable factors within reach.

Prostate cancer symptoms

Early prostate cancer almost always produces no symptoms at all. This is the single most important thing to understand about the disease.

The prostate is small, and a tumor forming within it does not press on anything or cause pain in its early stages. There is no "prostate pain" that signals early cancer. A man can have a curable, aggressive tumor and feel completely normal.

When symptoms do appear, they typically indicate either an enlarged prostate (most often BPH, not cancer) or cancer that has grown beyond the gland:

• Difficulty starting urination or a weak, interrupted stream

• Frequent urination, especially at night

• Pain or burning during urination

• Blood in the urine or semen

• Difficulty achieving an erection, or painful ejaculation

• Pain in the lower back, hips, pelvis, ribs, or thighs

• Unexplained weight loss or fatigue

• Weakness or numbness in the legs or feet

The last several suggest possible spread to bone or nerve compression and warrant urgent evaluation.

Important context: urinary symptoms are far more commonly caused by BPH or prostatitis than by cancer. Having them does not mean you have cancer. Not having them does not mean you don’t. Symptoms are simply not a reliable guide either way — which is the entire argument for screening.

Prostate cancer screening: who, when, and how often

Screening means testing men who feel fine, in order to find cancer early enough to matter. The primary tool is the PSA blood test, which measures prostate-specific antigen. A digital rectal exam (DRE) may be used alongside it, though its value as a standalone screening test is limited.

Guidelines differ, and it is worth understanding why. PSA screening reduces prostate cancer deaths, but it also detects some cancers that would never have caused harm — leading to biopsies and treatment some men did not need. Organizations weigh that tradeoff differently. Modern practice has narrowed the gap considerably, because MRI and biomarker testing now let us decide who actually needs a biopsy, and active surveillance lets us monitor low-risk cancers rather than treating them.

American Urological Association / Society of Urologic Oncology (2026 amendment)

The AUA and SUO released an updated Early Detection of Prostate Cancer Guideline in February 2026, containing 35 recommendations. Its core framework:

• Ages 45–50: offer a baseline PSA test to men at average risk, after a shared decision-making conversation.

• Ages 40–45: begin screening for men at increased risk — Black ancestry, a known germline mutation, or a strong family history.

• Ages 50–69: screen at intervals of roughly every 2 to 4 years, personalized based on the baseline PSA result, age, overall health, and life expectancy.

• Over 70: continue only selectively, based on health status and prior PSA values rather than age alone.

The 2026 amendment strengthened guidance on using MRI before an initial biopsy, updated the recommendations on biomarker-based risk stratification, and added new material on personalizing re-screening intervals and on the effect of 5-alpha reductase inhibitors on PSA readings.

U.S. Preventive Services Task Force

The USPSTF recommendation dates from 2018 and remains in force while an update is in progress. It recommends that men aged 55 to 69 make an individual decision about PSA screening in consultation with their clinician (Grade C), and recommends against routine PSA screening for men 70 and older (Grade D).

American Cancer Society

The ACS recommends an informed decision-making discussion beginning at age 50 for average-risk men with at least a 10-year life expectancy, age 45 for men at high risk (Black men, or a first-degree relative diagnosed before 65), and age 40 for men with multiple affected first-degree relatives.

What this means for you

If you are 45 or older — or 40 or older with Black ancestry, a family history, or a known genetic mutation — the reasonable step is a baseline PSA test and a conversation about what the number means for you specifically. A single PSA value in isolation tells you relatively little. Its trajectory over time, interpreted alongside your age, prostate size, and risk profile, tells you a great deal.

How prostate cancer is diagnosed

Diagnosis in 2026 looks different from diagnosis a decade ago. The old pathway sent nearly every man with an elevated PSA straight to a random 12-core biopsy. The current pathway adds several filtering steps first.

1. PSA testing and interpretation. Beyond the raw number, your urologist evaluates PSA density (PSA relative to prostate volume), PSA velocity (rate of change over time), and free-versus-total PSA ratio. An elevated PSA has many benign causes — BPH, prostatitis, recent ejaculation, cycling, catheterization, or urinary infection. A single high reading is a reason to investigate, not to panic.

2. Secondary biomarker tests. Blood, urine, and tissue tests including the 4Kscore, Prostate Health Index (phi), MyProstateScore 2.0, ExoDx, and SelectMDx can refine the probability that a clinically significant cancer is present. These are most useful in the gray zone, where the decision to biopsy is genuinely uncertain. The AUA advises against using them in men already assessed as low-risk.

3. Multiparametric MRI. This is the most significant change in prostate diagnosis in a generation. An mpMRI images the prostate before any biopsy and scores suspicious areas using the PI-RADS system (1 to 5). A reassuring MRI can spare some men a biopsy entirely; a suspicious one shows exactly where to aim. The 2026 AUA amendment upgraded its guidance on pre-biopsy MRI on the strength of accumulating evidence.

4. Targeted biopsy. When a biopsy is needed, an MRI-fusion biopsy overlays the MRI images onto live ultrasound, letting the urologist sample the specific suspicious lesion rather than sampling blindly. This finds more clinically significant cancers and fewer insignificant ones. The transperineal approach — through the skin between scrotum and rectum rather than through the rectal wall — is increasingly preferred because it dramatically reduces infection risk and reaches anterior tumors more reliably.

5. Staging imaging (if cancer is found). For intermediate- and high-risk disease, PSMA PET/CT has largely replaced conventional bone scan and CT. It detects prostate cancer cells anywhere in the body with far greater sensitivity, and it routinely changes management — finding disease that older imaging missed, and sparing some men futile local treatment.

6. Genetic and genomic testing. Two distinct tests, often confused:

• Germline testing examines your inherited DNA for mutations such as BRCA1/2, ATM, CHEK2, and HOXB13. It is recommended for men with metastatic, high-risk, or very-high-risk disease, and for those with a strong family history. Results affect treatment eligibility and have implications for your children and siblings.

• Tumor genomic testing (Decipher, Oncotype DX GPS, Prolaris) analyzes the biopsy tissue itself to predict how aggressively that particular cancer is likely to behave. Useful when deciding between surveillance and treatment, or whether to intensify therapy.

Understanding your pathology report: Gleason score and Grade Groups

Your biopsy pathology report is the single most important document in your case. Here is how to read it.

The Gleason score grades how abnormal the cancer cells look under a microscope. The pathologist identifies the two most prominent patterns, each graded 3 to 5, and adds them together. So a report reading "3+4=7" means the predominant pattern was grade 3 and the secondary pattern grade 4.

An important correction to older material still circulating online: the Gleason score does not meaningfully range from 2 to 10 anymore. Patterns 1 and 2 are no longer assigned to biopsy specimens. In current practice, the lowest diagnosable score is 6. A "6 out of 10" sounds alarming to patients when it is in fact the lowest possible grade — which is precisely why the Grade Group system was introduced by the International Society of Urological Pathology and is now standard on every report:

Note the distinction between Grade Group 2 and 3 — both are "Gleason 7," but which pattern predominates changes the prognosis substantially. If your report says 7, find out whether it is 3+4 or 4+3.

Your report will also state the number of cores positive out of the total sampled, the percentage of cancer in each core, and whether there is perineural invasion or extraprostatic extension. All of these feed into your risk category.

Staging and risk groups

Staging uses the AJCC TNM system — tumor extent (T), lymph node involvement (N), and distant metastasis (M) — combined with PSA level and Grade Group to produce an overall stage group.

• Stage I — Cancer confined to the prostate, not detectable by exam or imaging, Grade Group 1, PSA under 10.

• Stage II — Confined to the prostate, subdivided by Grade Group and PSA. IIA: Grade Group 1 with PSA 10–20. IIB: Grade Group 2. IIC: Grade Group 3 or 4.

• Stage III — IIIA: still organ-confined but PSA 20 or above. IIIB: extends beyond the prostate into nearby tissue such as the seminal vesicles, bladder neck, or rectum. IIIC: Grade Group 5 regardless of extent.

• Stage IV — IVA: spread to regional lymph nodes. IVB: spread to distant sites, most commonly bone, or to distant lymph nodes or organs.

For treatment decisions, urologists generally use NCCN risk groups, which combine the same variables into practical categories: very low, low, favorable intermediate, unfavorable intermediate, high, and very high risk. Your risk group, more than your stage number, determines which treatments are appropriate.

Prostate cancer treatment options

There is no single best treatment. The right choice depends on your risk group, age, life expectancy, urinary and sexual function, other medical conditions, and — legitimately — your own priorities. Two men with identical pathology can reasonably choose differently.

Active surveillance

For very low, low, and some favorable intermediate-risk cancers, the best treatment is often no immediate treatment. Active surveillance means close monitoring — PSA every 6 months, periodic MRI, repeat biopsy at intervals — with definitive treatment held in reserve if the cancer shows signs of progression.

This is not neglect. It is a deliberate, evidence-backed strategy that spares men the side effects of treatment they may never need. Long-term data show excellent cancer-specific survival, and roughly a third to half of men on surveillance eventually convert to treatment. Active surveillance is now the majority approach for Grade Group 1 disease in the United States, and appropriately so.

Distinct from this is watchful waiting, a less intensive approach for men with limited life expectancy, where treatment is given only for symptom relief.

Surgery: radical prostatectomy

Surgical removal of the prostate and seminal vesicles, usually with pelvic lymph node dissection for higher-risk disease. Robot-assisted laparoscopic prostatectomy is the standard approach in the U.S., offering magnified 3D visualization, precise instrument control, less blood loss, and faster recovery than open surgery.

Surgery is generally best suited to men with localized disease and a life expectancy of 10 or more years. Its advantages include complete pathological staging of the removed specimen, an easily interpreted PSA afterward (it should fall to undetectable), and the availability of radiation as a salvage option if needed.

The two principal side effects are urinary incontinence and erectile dysfunction. Both are strongly influenced by surgical technique — particularly nerve-sparing — and by surgeon volume and experience. Most men regain urinary continence within 3 to 12 months. Erectile recovery is slower and less certain, depending heavily on pre-operative function, age, and whether the neurovascular bundles could be preserved.

Dr. Samadi’s SMART (Samadi Modified Advanced Robotic Technique) approach was developed to maximize preservation of the nerves and urinary sphincter. Learn more about robotic prostatectomy →

Radiation therapy

Comparably effective to surgery for localized disease, with a different side-effect profile — generally less immediate incontinence, but more bowel irritation and a gradual rather than immediate decline in erectile function.

• External beam radiation (EBRT/IMRT): typically delivered over several weeks.

• Stereotactic body radiation therapy (SBRT): high-dose treatment in 5 or fewer sessions, now well supported for low- and intermediate-risk disease.

• Brachytherapy: radioactive seeds or temporary high-dose sources placed directly in the prostate; can be used alone or as a boost alongside EBRT.

• Proton therapy: available at select centers; theoretical dosimetric advantages, but no clear proven superiority over modern photon techniques.

Higher-risk disease is generally treated with radiation plus hormone therapy, which meaningfully improves survival compared with radiation alone.

Focal therapy

Treats only the tumor and a margin of surrounding tissue rather than the whole gland, using HIFU, cryotherapy, irreversible electroporation, or transurethral ultrasound ablation (TULSA). The appeal is markedly lower rates of incontinence and erectile dysfunction.

The honest caveat: long-term cancer-control data remain less mature than for surgery or radiation, and focal therapy is best considered for carefully selected men with a single well-defined lesion — ideally within a clinical trial or a registry at an experienced center.

Hormone therapy (androgen deprivation therapy)

Because prostate cancer depends on androgens, lowering testosterone slows it. ADT is delivered by LHRH agonists or antagonists, or by orchiectomy. It is used alongside radiation for higher-risk localized disease, for recurrence, and as the backbone of treatment for metastatic disease.

Side effects are significant and worth discussing frankly: hot flashes, loss of libido, erectile dysfunction, fatigue, muscle loss, bone density loss, metabolic changes, and mood effects. Duration should be individualized — an active area of research is determining who needs long courses and who can safely have less.

Androgen receptor pathway inhibitors (ARPIs)

Abiraterone, enzalutamide, apalutamide, and darolutamide block androgen signaling more completely than ADT alone. Over the past several years these have moved steadily earlier in the disease course, and combining ADT with an ARPI from the start of metastatic hormone-sensitive disease is now standard, with clear survival benefits.

Chemotherapy

Docetaxel, and later cabazitaxel, remain important — particularly as part of upfront combination therapy for high-volume metastatic disease and for castration-resistant disease.

Targeted therapy: PARP inhibitors

For men with mutations in DNA damage repair genes — most importantly BRCA2 — PARP inhibitors including olaparib, rucaparib, talazoparib, and niraparib exploit the tumor’s inability to repair its own DNA. Originally approved for castration-resistant disease, they have now moved into the metastatic hormone-sensitive setting. This is why germline and tumor testing matters practically, not just academically.

Radioligand therapy

Lutetium-177 vipivotide tetraxetan (Pluvicto) delivers targeted radiation directly to PSMA-expressing cancer cells. Approved in 2022 for PSMA-positive castration-resistant disease after ARPI and chemotherapy, expanded in March 2025 to the pre-chemotherapy setting, and in July 2026 approved in combination with an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer. PSMA is expressed in more than 80% of prostate cancers.

Radium-223 (Xofigo) remains an option for symptomatic bone metastases without visceral disease.

Immunotherapy

Sipuleucel-T is an autologous cellular immunotherapy for minimally symptomatic castration-resistant disease. Pembrolizumab is an option for the small subset of tumors that are MSI-high or mismatch-repair deficient. Bispecific T-cell engagers targeting PSMA and STEAP1 are in active trials and represent one of the more promising near-term directions.

Clinical trials

Worth asking about at every stage, not just as a last resort. Many of the treatments now considered standard were available only through trials five years ago.

Prostate cancer survival rates

Based on SEER data, five-year relative survival rates are:

Two things to keep in mind when reading these figures. First, they reflect men diagnosed several years ago and do not capture the benefit of treatments approved since. Second, they are population averages — your individual outlook depends on your Grade Group, PSA, extent of disease, genomic profile, response to treatment, and overall health.

The contrast between roughly 100% and roughly 37% is the entire case for screening, stated as plainly as it can be stated.

Schedule Your Consultation With NYC's Leading Urologist

Take control of your health today. Whether you are seeking a second opinion, managing an elevated PSA, or weighing treatment options after a diagnosis, Dr. David Samadi and the team at Prostate Cancer 911 provide world-class care in Midtown Manhattan.

Book Your Appointment Now

Office: 485 Madison Ave, 21st Floor, New York, NY 10022 Phone: (212) 365-5000

Sources

• American Cancer Society. Cancer Facts & Figures 2026; Key Statistics for Prostate Cancer.

• Siegel RL, et al. Cancer Statistics, 2026. CA: A Cancer Journal for Clinicians.

• Lin DW, Carlsson S, Filson CP, et al. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). Journal of Urology.

• U.S. Preventive Services Task Force. Prostate Cancer: Screening. Final Recommendation Statement, 2018 (update in progress).

• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer, v2.2026.

• NCI Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Prostate Cancer.

• FDA/Novartis. Pluvicto approvals, March 2025 and July 2026.

This page is for general education and does not substitute for personalized medical advice. Discuss your individual situation with a qualified physician.